Ácido hialurônico
Studied in stable disease as a gentler option than collagenase.
An internal scar causes curvature and pain. Research is small and mostly academic; experts estimate 5 to 10 years to a new treatment. 2026's news comes from combining old drugs.
The latest developments, newest first.
Acting early, before the scar hardens, may be key for antifibrotics.
UK pilot study published in the Journal of Sexual Medicine. Authors call for a prospective trial.
Each column is a step on the road to the pharmacy. Colors show the type of treatment.
Studied in stable disease as a gentler option than collagenase.
133 men in the acute phase: 43% improved curvature vs 15% untreated; pain nearly vanished. Needs a controlled trial.
Prevented cells from turning fibrotic in the lab.
Possible alternative with fewer side effects than current collagenase.
Candidates that looked promising and were stopped. Most treatments tested never reach the market.
— · Urology guidelines advise against them for lack of proven benefit.
None yet. Current treatment: Collagenase injections, traction and surgery.
Fasevia tracks 4 candidates: Ácido hialurônico (Phase 2); Tadalafila/sildenafila + tamoxifeno (Lab / pilot); Inibidores de PDE1/PDE4 (Lab / pilot); Colagenase de kiwi (Lab / pilot).
The furthest along today is Ácido hialurônico (Vários centros), in phase 2. Studied in stable disease as a gentler option than collagenase.
A drug has to complete phase 3 and be reviewed by health agencies such as the FDA or EMA, which usually takes several years. The leading candidate today is in phase 2.